The FDA's acceptance of the supplemental application for VABYSMO is a significant regulatory milestone that could strengthen Genentech's competitive position in the ophthalmology market. This development necessitates close monitoring of the approval process and market dynamics as competitors may respond with their own strategies. Regulatory context from FDA (FDA AP — VABYSMO (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (0 high-relevance).